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ABSTRACT  
Generalized pustular psoriasis (GPP) is a rare and serious immune-mediated skin disorder that is characterized by a widespread eruption of 
sterile and subcorneal pustules.  In the present study we investigated the efficacy of Cyclosporine A (Cy A) in treatment of 9 adults wit h drug-
refractory GPP viz. topical Corticosteroids, retinoids, methotrexate and narrow-band ultraviolet light exposure (UVB).  Initially; they were 
resuscitated as burn patients. Cy A was administered on day 1 at a dose of 100 mg twice daily either in the form of syrup or Neoral capsules.  In 
most patients, skin lesions had healed by 6 weeks and the dose of Cy A was reduced to minimum to prevent further recurrence.  Seven patients 
had required 50 mg twice daily and 2 were controlled with 50 mg am and 25 mg pm.  O n follow up, there was no serious relapse, liver and 
kidney disease.  Minor complications included; hirsutism and dark skin (n: 5) and gingival hyperplasia (n: 2). Trial to replace Cy A with 
Tacrolimus (Prograf) failed to maintain remission.  In conclusion; Cy A is a safe and effective treatment for GPP. 
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INTRODUCTION 
Psoriasis (P) is a common skin disease affecting 2% of 
people living in the United States.   It is an autoimmune 
disease with genetic predisposition associated with multiple 
triggering environmental factors [1].  Plaque and guttate 
types are the most common presentations of P and both 
account for over 90% of cases.  On the other hands, Pustular 
type is a rare and serious form of P.  It is characterized by a 
widespread eruption of sterile, subcorneal pustules.  It has a 
reported annual incidence rate of less than 1 per 1,000,000 
inhabitants and prevalence less than 2 per 1,000,000 
populations.  It affects all races with an equal sex 
predisposition and the average age of patients is 50 years 
[2].  It may rarely affect children between 2-10 years yet 
contrary to adults it may remit with time [3].  It can present 
with limited and chronic lesions viz. ring-shaped (annular, 
or circinate), palms and soles (palmoplanter pustulations), 
fingertips and nails (acrodermatitis continua of Hallopeau) 
and very rarely in infants.  Two serious presentations of 
pustular P were reported viz. during pregnancy (impetigo 
herpetiformis) and generalized pustular P (GPP).  The latter 
may present suddenly, and without history of P, with wide 
spread lesions associated with systemic febrile illness (von 
Zumbusch type) [4].  The chronic forms of P are associated 
with social maladjustment and psychological disorders while 
the serious ones are associated with high morbidity and 
mortality due to the inhererent side-effects of 
immunosuppressive therapy, malnutrition and infections 
[2].  In our prospective study, we aimed at providing a safe 
modality for management of the most serious one viz. GPP 
by using maintenance Cyclosporine A (Cy A).  
PATIENTS AND METHODS 
During the period January 2014 to December 2019, 9 adult 
patients with refractory GPP were selected for treatment 
with CyA.  Patients were included if they had: (a) age > 14 
years; (b) GPP diagnosed clinically and confirmed by 
histopathological examination; (c) severe and extensive 
disease with psoriasis area and severity index (PASI) > 70 
[5]; (d) persistent or relapsing disease despite treatment 
with topical Corticosteroids, retinoids, methotrexate and 
narrow-band ultraviolet light exposure (UVB); (e) no 
evidence of recent or recurrent exposure to solar or 
traumatic injuries, primary skin infections, HIV, drugs viz. 
lithium, beta blockers, antimalarial, antibiotics (penicillin 
and sulphonamides), psychotropic agenys (nitrazepam and 
trazodone), amiodrone, Mestranol, Morphine, NSAIDS and 
sudden withdrawal of corticosteroids.  Initially, all patients 
were treated, as burn cases, with intravenous fluids 
with/without human albumin to control shock-state and 
replace the deficient electrolytes.  They also had received 
broad-spectrum antibiotics to protect against skin and chest 
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infections as well as topical treatments.  Cy A was given, on 
day 1, orally, as syrup or neural capsules, in an initial dose of 
3 mg/kg/day in 2 divided doses.  Subsequently, the dose was 
further adjusted every 2 weeks to achieve a trough level 
within therapeutic range (100-400 ug/L; Abbott Architect 
Chemiluminescent Microparticle immunoassay).  After their 
initial in-hospital stabilization, patients were assessed every 
2 weeks as outpatients for 6 weeks.  They were assessed 
clinically using PASI scores and with laboratory tests that 
included complete blood count as well as renal and liver 
function tests.  After 6 weeks of stabilization; patients were 
seen on monthly basis and the dose of Cy A was reduced 
gradually, by 25 mg/day every month, till reaching the 
minimal maintenance dose. 
RESULTS 
The demographical data on the patients studied and their 
response to Cy A after 6 weeks and by the end of the study is 
summarized in Table 1.  All patients were white adults and 
with equal sex distribution.  They had severe psoriasis for a 
median of 5 months yet it was refractory to the above-
mentioned conventional treatments.  In most patients, skin 
lesions had healed rapidly within 6 weeks and PASI scores 
had dropped from 71.7+0.5 to 4.9+1 by 6 weeks and 3.2+1 
after 43.4+9 months of follow up. Subsequently, the dose of 
Cy A was reduced gradually to minimum to prevent further 
recurrence.  Seven patients had required 50 mg twice daily 
and 2 were controlled with 50 mg am and 25 mg pm.  On 
follow up; there was no serious relapse.  Their liver and 
kidney functions were normal.  The latter was confirmed by 
24 hour urine collections that had shown no significant 
decrease in creatinine clearance or emergence of significant 
proteinuria.  Minor complications included; hirsutism and 
dark skin (n: 5) and gingival hyperplasia (n: 2).  To avoid 
such side-effects; Cy A was replaced with Tacrolimus 
(Prograf).  However, Tacrolimus failed to maintain such 
remissions.
 
 
 
Figure 1 Showing the foot of a patient with generalized pustular psoriasis before (A) and after treatment with Cyclosporine A 
(B). 
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DISCUSSION 
Cy A was first approved to prevent the body from rejecting a 
transplanted organ. When given to organ-transplant 
recipients who had psoriasis, patients discovered that the 
medicine also effectively treated their psoriasis. Since that 
discovery, the U.S. Food and Drug Administration (FDA) has 
approved Cy A to treat psoriasis in adults who have 
extensive or disabling psoriasis [6]. There is now strong 
circumstantial evidence that psoriatic skin lesions occur 
when CD4+ T lymphocytes infiltrate the epidermis of 
genetically susceptible subjects [7]. The genetic factors 
predisposing to the psoriatic epidermal response have not 
been characterized, but are likely to entail abnormal 
homeostatic control of keratinocyte growth, including 
hyperproliferative response to products of activated T 
lymphocytes [8].  The initiating factor is an injury or 
microbial infection.  The recruited T-lymphocytes infiltrate 
superficial dermis and produce interleukins and TNF as well 
as increase production of antigen producing cell (APC).  
Subsequent cascade of events include; (a) epidermal 
acanthosis with parakeratosis leading to elongated rete 
ridges and superficial pinpoint bleeding when the keratin 
scale peel off easily (b) increase keratin production leading 
to thick skin and broad scales [9].  In case of pustular P; the 
neutrophils infiltrate epidermis and collect subcorneal in the 
acanthotis epidermis leading to sterile pustules.  These facts 
are essential for understanding the role of Cy A in treatment 
of P.  The first is its essential role in blocking IL-2 which is 
essential in the cascade of T-cell recruitment [10]. Hence, it 
works fast.  Moreover, it does not eliminate the disease 
which is a genetic-predisposition and will be life-long.  The 
latter is essential to avoid recurrence of P after 120 days 
following a 4-8 weeks treatment-regimen [11].  As with 
organ transplant patients; the minimal long-term 
maintenance dose to avoid relapses is < 3 mg/kg/day or 
with a trough levels < 150 ug/L, to minimize risk of 
interstitial kidney fibrosis [12].  Interestingly, Tacrolimus 
did not improve GPP as Cy A.  Both drugs inhibit the action 
of the phosphatase calcineurin which regulates the transport 
of NFAT (nuclear factor of activated T-cells, which is a 
transcription factor regulating lymphokine gene 
transcription.   However, Cy A and Tacrolimus exert their 
cellular effects on the action of calcineurin through different 
cytoplasmatic receptors, as Cy A binds to cyclophilins and 
Tacrolimus binds to FK-binding proteins [13].  The latter 
may explain that phenomenon.  In conclusion; Cy A is an 
effective and safe maintenance treatment for GPP.  
REFERENCES: 
1- Alexis AF, Blackcloud P. Psoriasis in skin of color: 
epidemiology, genetics, clinical presentation, and treatment 
nuances.  J Clin Aesthet Dermatol. 2014; 7:16-24.   
2- Augey F, Renaudier P, Nicolas JF. Generalized pustular 
psoriasis (Zumbusch): a French epidemiological survey. Eur J 
Dermatol 2006; 16: 669-673.  
3- Popadic S, Nikolic M. Pustular psoriasis in childhood and 
adolescence: a 20-year single-center experience. Pediatr 
Dermatol 2014; 31:575-579. 
4- Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis 
and classification of psoriasis. Autoimmunity Reviews 2014; 
13: 490–495. 
5- Schmitt J, Wozel G.  The psoriasis area and severity index is 
the adequate criterion to define severity in chronic plaque-
type psoriasis.  Dermatology 2005; 210: 194-199. 
6- Mueller W, Herrmann B. Cyclosporin A for psoriasis. N 
England J Med 1979; 301: 555. 
7- Sackstein R, Falanga V, Streilein J W, Chin Y H. Lymphocyte 
adhesion to psoriatic dermal endothelium in is mediated by a 
tissue-specific receptor/ligand interaction.  
J Invest Dermatol 1988; 91: 423-428. 
8- Valdimarsson H, Baker B S, Jonsdottir I, Powles A, Fry L. 
Psoriasis: a disease of abnormal keratinocyte proliferation 
induced by T lymphocytes. Immunol Today 1986; 7: 256-259. 
9- Naik HB, Cowen EW.  Autoinflammatory pustular neutrophilic 
diseases.  Dermatol Clin 2013; 31: 405-425. 
10- Matsuda S, Koyasu S.  Mechanisms of action of cyclosporine.  
Immunopharmacol 200; 47: 119–125.  
11- Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R. Low-dose, 
short-term ciclosporine (Neoral) therapy is effective in 
improving patients’ quality of life as assessed by Skindex-16 
and GHQ-28 in mild to severe psoriasis patients. J Dermatol 
2011; 38:465–472. 
12- Slattery C, Campbell E, McMorrow T, Rayan MP.  Cyclosporine 
A-induced renal fibrosis.  Am J Pathol 2005; 167: 395-407. 
13- Penninga L, Møller CH, Gustafsson F, Steinbrüchel DA, Gluud 
C. Tacrolimus versus cyclosporine as primary 
immunosuppression after heart transplantation: systematic 
review with meta-analyses and trial sequential analyses of 
randomised trials.  Eur J Clin Pharmacol  2010; 66:1177-1187. 
 
 
